SAN DIEGO, Nov. 3 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-101, a potent small molecule for treatment of Alzheimer’s disease. These studies demonstrate that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into clinical trials in Q1 2009. Results of the studies will be presented at the 9th International Conference -- AD/PD 2009 -- Prague, Czech Republic, March 11-15, 2009.
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
CONTACT: Yan Lavrovsky, CEO of Avineuro Pharmaceuticals, Inc.,
+1-858-436-1537, fax, +1-858-228-9798, ylavrovsky@avineuro.com
Web site: http://www.avineuro.com/
